Novo Nordisk To Invest $22 Million in US Finished-Products Mfg PlantBy
Following an announced $65-million investment in February (2018), Novo Nordisk plans to invest an additional $22 million in its finished-products manufacturing plant in Clayton, Johnston County, North Carolina. This is the company’s fourth expansion at the site since 2010.
Novo Nordisk, which employs almost 1,200 manufacturing workers in Johnston County, will invest $22 million at its Clayton facility. The move comes 10 months after the company unveiled plans for a $65-million expansion there.
Novo Nordisk’s manufacturing facility in Clayton is responsible for the formulation, filling, inspection, assembly and packaging of diabetes and obesity medicines. The site opened in 1993. In 2010, the company launched a 120-job expansion there as part of a business partnership with Nypro, a plastics manufacturer. In March 2016, Novo Nordisk broke ground for a new $1.8-billion production facility in Clayton to produce active pharmaceutical ingredients (API) for a range of Novo Nordisk’s current and future diabetes medicines (glucose-dependent insulinotropic peptide (GLP-1) drugs and insulin medicines). The new site, which was scheduled to be operational in 2020 at the time of the announcement, is situated adjacent to Novo Nordisk’s production site in Clayton responsible for formulation, filling and packaging of diabetes medicines. That plant also assembles and packages the company’s prefilled insulin devices for the US market. The $1.8-billion investment in the API facility was part of $2-billion investment, announced by the company in August 2015, into its diabetes medicine manufacturing network, which also included investments in Malov, Denmark and Kalundborg, Denmark.
Source: Johnston County North Carolina Economic Development Office